Standout Papers

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolis... 2009 2026 2014 2020 1.8k
  1. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism (2013)
    Sam Schulman, Clive Kearon et al. New England Journal of Medicine
  2. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes (2019)
    Julio Rosenstock, Steven E. Kahn et al. JAMA
  3. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk (2018)
    Julio Rosenstock, Vlado Perkovic et al. JAMA
  4. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (2009)
    Sam Schulman, Clive Kearon et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 102 standout
Sub-graph 1 of 15

Citing Papers

Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
2022 Standout
Acute Pulmonary Embolism
2022 Standout
23 intermediate papers

Works of David Baanstra being referenced

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
2013 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
David Baanstra 2445 2277 1159 9 3.8k
Urszula Masiukiewicz 1853 1447 1932 21 4.0k
Janet Schnee 4750 3967 647 41 6.0k
Jonathan L. Halperin 2473 1543 458 21 6.6k
Peter Nicol 1480 1344 878 17 2.7k
for the Mexican Nephrology Collaborative Study Group 1143 364 700 23 4.7k
Susan R. Heckbert 1409 1996 220 26 3.4k
Jesper Lindhardsen 3056 903 300 65 6.5k
Alan K. Jacobson 4243 2133 185 36 5.4k
Jean‐Philippe Collet 5689 901 235 24 6.6k
Melina Verso 1592 2439 250 59 3.5k

All Works

Loading papers...

Rankless by CCL
2026